Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS.

Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS.

A decision-analytical simulation model was constructed to perform a pharmacoeconomic analysis of the following 3 treatment strategies for previously untreated cytomegalovirus (CMV) retinitis in patients with AIDS: (i) intravenous foscarnet (IVF) for induction and maintenance therapy; (ii) intravenou...

Full description

Bibliographic Details
Main Authors:	Griffiths, R, Bleecker, G, Jabs, D, Dieterich, D, Coleson, L, Winters, D, Wolitz, R, Steinberg, E
Format:	Journal article
Language:	English
Published:	1998

Similar Items

PHARMACOECONOMIC BENEFITS OF CYTOMEGALOVIRUS INFECTION PROPHYLACTIC STRATEGY FOR RENAL TRANSPLANT RECIPIENTS
by: V. V. Ryazhenov, et al.
Published: (2011-06-01)

Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic.
by: David Heiden, et al.
Published: (2007-12-01)

Optimal management of cytomegalovirus retinitis in patients with AIDS
by: Michael W Stewart
Published: (2010-04-01)

Treatment of cytomegalovirus retinitis
by: B. S. Pershin, et al.
Published: (2019-11-01)

Treatment of Retinal Separation in HIV-infected Patients with Cytomegalovirus Retinitis
by: A. L. Onischenko, et al.
Published: (2017-03-01)

A Mouse Model That Mimics AIDS-Related Cytomegalovirus Retinitis: Insights into Pathogenesis
by: Jay J. Oh, et al.
Published: (2021-07-01)

Prevalence and clinical management of cytomegalovirus retinitis in AIDS patients in shanghai, china
by: Shi Ying, et al.
Published: (2011-11-01)

SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis
by: Christine I. Alston, et al.
Published: (2019-04-01)

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant
by: C. Muccioli, et al.
Published: (2000-07-01)

Spectral-domain optical coherence tomography finding in cytomegalovirus retinitis in AIDS patients
by: Yan Sheng, et al.
Published: (2020-11-01)

Effect of individualized therapy for AIDS patients with cytomegalovirus retinitis in intravitreal ganciclovir injections
by: Lian-Yong Xie, et al.
Published: (2019-08-01)

Pharmacoeconomic analysis of Cellex® in the treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-06-01)

Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Comparison of two different intravitreal treatment regimens combined with systemic antiviral therapy for cytomegalovirus retinitis in patients with AIDS
by: Xuemei Liang, et al.
Published: (2023-07-01)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
by: A Jayaprakash Patil, et al.
Published: (2010-03-01)

Pharmacoeconomics of spastic cerebral palsy
by: R. I. Yagudina, et al.
Published: (2018-02-01)

Human leucocyte antigen profile in patients with aids and cytomegalovirus retinitis with and without macular involvement
by: Nivaldo Vieira de Souza, et al.
Published: (2015-02-01)

Human leucocyte antigen profile in patients with aids and cytomegalovirus retinitis with and without macular involvement
by: Nivaldo Vieira de Souza, et al.
Published: (2015-02-01)

Pharmacoeconomic
by: Weiam A. Harwan, et al.
Published: (2014-06-01)

Pharmacoeconomic analysis of Cocarnit® complex as treatment for diabetic polyneuropathy
by: D. Yu. Belousov, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of Xeomine® for treatment patients with focal dystonia
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Pharmacoeconomic aspects of biosimilars
by: A A Tryakin, et al.
Published: (2017-01-01)

Unilateral ischemic maculopathy associated with cytomegalovirus retinitis in patients with AIDS: Optical coherence tomography findings
by: J Fernando Arevalo, et al.
Published: (2015-01-01)

Cystoid macular edema secondary to immune recovery uveitis in a man with cytomegalovirus retinitis and AIDS
by: Kathir Yoganathan
Published: (2010-09-01)

Cytomegalovirus retinitis and antiretroviral treatment: A fifteen year experience
by: Serisha Jay Narain, et al.
Published: (2022-03-01)

Pharmacoeconomic aspects of COVID-19 treatment
by: I. V. Rogova, et al.
Published: (2021-10-01)

Pharmacoeconomic particulars of ovaries cancer’s treatment
by: V N Zhurman, et al.
Published: (2015-06-01)

Pharmacoeconomic considerations in the treatment of breast cancer
by: Athanasios Pallis, et al.
Published: (2010-06-01)

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain
by: Robert Morlock, et al.
Published: (2017-10-01)

Case Report: Cytomegalovirus-specific T-lymphocyte infusion for resistant cytomegalovirus retinitis
by: Tal Saban, et al.
Published: (2023-07-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomics of HIV-infection
by: R. I. Yagudina, et al.
Published: (2018-02-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Active cytomegalovirus retinitis after the start of antiretroviral therapy
by: Heiden, D, et al.
Published: (2018)

Cytomegalovirus retinitis after treatment with topical difluprednate in an aphakic eye of an immunocompetent patient
by: Richard I. Kaplan, et al.
Published: (2019-12-01)

Challenges in Cytomegalovirus (CMV) Retinitis Management
by: Denisa Rosati, et al.
Published: (2019-09-01)

Cytomegalovirus retinitis mimicking intraocular lymphoma
by: Patrick Gooi, et al.
Published: (2008-12-01)

Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema
by: A. E. Cheberda, et al.
Published: (2018-05-01)

A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine
by: Bhambri R, et al.
Published: (2015-01-01)